IP Library Granted Patent US 6,964,771
Granted Patent B1
US 6,964,771 · App. 08/923,783 · Granted Nov 15, 2005

Method for stably incorporating substances within dry, foamed glass matrices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,964,771
App. No.
08/923,783
Granted
Nov 15, 2005
Kind
B1
Abstract

The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

Claims (62)

1. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and an organic solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent.

2. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and a solvent(s) for the glass matrix-forming material, wherein the solvent(s) is a combination of aqueous and organic liquids;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent.

3. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the class matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least one volatile salt to the mixture before step (c).

4. The method according to claim 3 , wherein the volatile salt is selected from the group consisting of ammonium acetate, ammonium bicarbonate, and ammonium carbonate.

5. The method according to claim 3 , wherein the volatile salt is present in an amount from about 0.01 to 5 M.

6. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least one salt that decomposes under less than atmospheric pressure to give a gaseous product to the mixture before step (c).

7. The method according to claim 6 , wherein the decomposing salt is selected from the group consisting of sodium bicarbonate and sodium metabisulphite.

8. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least one volatile organic liquid to the mixture before step (c).

9. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least one additive to the mixture before step (c), wherein the additive is a foam stabilizing agent, wherein the foam stablization agent is a viscosity modifier, and wherein the viscosity modifier is a guar gum.

10. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least one additive to the mixture before step (c), wherein the additive is a foam stabilizing agent, and wherein the foam stabilization agent is a surface-active amphipathic molecule.

11. A method for producing foamed glass matrices (FGMs) containing a biologically active agent, comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent, and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the method further comprises the step of adding at least additive that is an inhibitor of the Maillard reaction to the mixture before step (c).

12. A method for preserving a biologically active agent within a foamed glass matrix (FGM) comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent to be preserved and solvent(s) for the class matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the biologically active agent to be preserved is a vaccine; and

wherein the vaccine comprises Hepatitis B Surface Antigen, measles virus, or oral polio virus.

13. A method for preserving a biologically active agent within a foamed glass matrix (FGM) comprising the steps of:

(a) preparing an initial mixture comprising at least one glass matrix-forming material containing a biologically active agent to be preserved selected from the group consisting of a therapeutic agent, a prophylactic agent, a pharmaceutically effective substance and a diagnostic reagent and solvent(s) for the glass matrix-forming material;

(b) evaporating a portion of the solvent(s) from the mixture to obtain a syrup;

(c) boiling the syrup under less than atmospheric pressure to produce foaming of the syrup; and

(d) continuing step (c) until the boiling results in the formation of a solid foam and produces a foamed glass matrix containing the biologically active agent;

wherein the biologically active agent to be preserved is dissolved in the mixture.

Assignments (3)
CHANGE OF NAME Recorded Dec 26, 2006
From: ELAN DRUG DELIVERY LIMITED
To: QUADRANT DRUG DELIVERY LIMITED
Reel/Frame 018668/0751 →
CHANGE OF NAME Recorded May 27, 2003
From: QUADRANT HOLDINGS CAMBRIDGE LIMITED
To: QUADRANT HEALTHCARE (UK) LIMITED
Reel/Frame 014090/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2003
From: QUADRANT HEALTHCARE (UK) LIMITED
To: ELAN DRUG DELIVERY LIMITED
Reel/Frame 013964/0452 →